Resumo

MALDONADO, Genessis; GUERRERO, Roberto; LNTRIAGO, Maria  e  RIOS, Carlos. D-Dimer trend in a long-term rheumatoid arthritis patient with tofacitinib treatment and recent COVID-19 infection. Rev.Colomb.Reumatol. [online]. 2022, vol.29, suppl.1, pp.84-87.  Epub 04-Fev-2024. ISSN 0121-8123.  https://doi.org/10.1016/j.rcreu.2021.06.003.

The SARS-CoV-2 virus was first identified in December 2019, the infection was named COVID-19. The initial symptoms and evolution of the disease have been described over the past year. The virus has been shown to increase the risk of thromboembolic events due to the hypercoagulable state triggered by systemic endothelial inflammation. We present the case of a patient with a history of rheumatoid arthritis under prolonged treatment with tofacitinib, who presented COVID-19 and subsequently developed a hypercoagulable state of approximately 6 months' duration. The possible association between viral infection and the use of tofacitinib is debated.

Palavras-chave : COVID-19; Hypercoagulability; Tofacitinib; Rheumatoid arthritis.

        · resumo em Espanhol     · texto em Inglês     · Inglês ( pdf )